Pharmaceuticals News and Research

RSS

Results of two pivotal Phase III clinical trials with oral FTY720 published

Results of the TRANSFORMS and FREEDOMS studies, the two pivotal Phase III clinical trials with oral FTY720 (fingolimod), have been published in The New England Journal of Medicine, providing comprehensive evidence to support the efficacy and safety profile of this first-in-class therapy for multiple sclerosis (MS).

21 Jan 2010

Benefits of NIH funding through the Recovery Act

In advance of the one-year anniversary of the Recovery and Reinvestment Act's enactment on February 17, twenty of the nation's leading research institutions, patient advocates and biomedical industry have released a detailed report on how Recovery Act funding of medical research through the National Institutes of Health (NIH) is at work across the country in the service of better health and a healthier economy.

21 Jan 2010

Phase 3 clinical trial results of Inspire Pharmaceuticals' PROLACRIA announced

Inspire Pharmaceuticals, Inc. announced today that its Phase 3 clinical trial (Trial 03-113) of PROLACRIA™ (diquafosol tetrasodium ophthalmic solution) 2% for the treatment of dry eye disease did not meet its primary endpoint (p = 0.526) or its secondary endpoint (p = 0.368).

21 Jan 2010

UnitedHealth Group announces its revenues and net earnings in 2009

UnitedHealth Group today reported growth in revenues and net earnings per share in 2009. The Company earned $0.81 per share in the fourth quarter, bringing full year 2009 net earnings to $3.24 per share.

21 Jan 2010

USPTO issues Notice of Allowance for IntelGenx's bupropion patent

IntelGenx Corp. ("IntelGenx") today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a formal Notice of Allowance for a key patent application protecting IntelGenx's CPI-300, a novel, high strength formulation of bupropion hydrochloride ("HCl"), the active ingredient in Wellbutrin XL(R).

21 Jan 2010

Tufts CSDD: Orphan product designations increased up to 425 in 2006-08

The number of orphan product designations in the U.S. more than doubled during the last decade, reflecting growing interest by pharmaceutical and biotech companies in developing products to treat orphan diseases, according to a study recently completed by the Tufts Center for the Study of Drug Development.

21 Jan 2010

Shandong Luoxin Pharmacy Stock chosen to list its ADRs on OTCQX

Pink OTC Markets Inc., the leading electronic inter-dealer quotation system, trading technology and financial information provider for Over-the-Counter (OTC) securities, today announced that Shandong Luoxin Pharmacy Stock Co., Ltd., a leading Chinese pharmaceutical company, has chosen to list its American Depositary Receipts (ADRs) on OTCQX®.

21 Jan 2010

Men who buy fake internet drugs for ED problems face significant health risks

Men who buy fake internet drugs for erection problems can face significant risks from potentially hazardous contents and bypassing healthcare systems could leave associated problems like diabetes and high blood pressure undiagnosed.

21 Jan 2010

Simulations Plus board authorizes renewed share repurchase program

Simulations Plus, Inc., the leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that its board of directors has authorized a renewed share repurchase program effective Monday, February 15, 2010.

21 Jan 2010

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

pSivida Corp., a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6th Annual Diabetes Conference in London, on Friday, January 22.

21 Jan 2010

BIO commends GSK and Alnylam’s efforts to foster new therapies for neglected diseases

The Biotechnology Industry Organization (BIO) applauds the joint efforts of BIO members GlaxoSmithKline and Alnylam Pharmaceuticals to encourage research to accelerate medical therapies for neglected diseases and today’s announcement of the selection of BIO Ventures for Global Health (BVGH) as the administrator of the Intellectual Property (IP) Pool.

21 Jan 2010

Medco Health Solutions launches Medco TRC for oncology patients

Medco Health Solutions, Inc. today announced the launch of the Medco Therapeutic Resource Center® (TRC) for oncology patients headquartered in Whitestown, Ind., where specialist pharmacists will manage the company's more than 850,000 patients currently living with cancer, one of the fastest growing segments of healthcare.

21 Jan 2010

Emerging Healthcare Solutions and ThromboVision complete due diligence process under new option agreement

Emerging Healthcare Solutions, Inc. and ThromboVision have completed phase one of their due diligence process under their new option agreement.

21 Jan 2010

Healthcare industry in Asia Pacific to grow up to US$349 billion by 2012

Frost & Sullivan believes that the healthcare industry is undergoing a paradigm shift from "sickness care" to "wellness". Focused on the 5 Ps – Preventive, Pre-emptive, Personalized, Predictive and Personal Responsibility – the healthcare industry in Asia Pacific is expected to grow to US$349 billion by 2012.

21 Jan 2010

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled "Compositions and methods for enzymatic detachment of bacterial and fungal biofilms" by IP Australia (Australian Patent and Trademark Office).

21 Jan 2010

New survey: Nurses should have more influence on health care services, say opinion leaders

From reducing medical errors, to increasing the quality of care, to promoting wellness, to improving efficiency and reducing costs, a new survey finds that an overwhelming majority of opinion leaders say nurses should have more influence.

21 Jan 2010

GSK to offer scientists access to compounds, lab space to fight malaria

Drugmaker GlaxoSmithKline (GSK)'s Chief Executive Officer Andrew Witty on Tuesday unveiled the company's plans to allow "free access to its library of 13,500 potential malaria treatments and devote the profits from its experimental [RTS,S] vaccine to battling tropical illnesses that beset poor countries," Bloomberg reports (Randall, 1/20).

21 Jan 2010

AMAG Pharmaceuticals prices public offering of common stock

AMAG Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $48.25 per share.

21 Jan 2010

Health shares rise with speculation regarding Massachusetts election

Health shares rose Tuesday as traders considered the prospect that a Republican victory in the special Senate election in Massachusetts could jeopardize the health reform legislation.

21 Jan 2010

Companies overseeing prescription benefits poised for growth

Pharmacy benefit management companies, the third-party administrators for prescription drug programs, have seen a boom in business. NPR reports they are "now poised for even more growth, as baby boomers age and Congress prepares to insure more Americans. ..."

20 Jan 2010